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NY 14263, USAIntratumoral dendritic cells play an important role in stim-
ulating cytotoxic T cells and driving antitumor immunity.
Using a metastatic ovarian tumor model in syngeneic mice,
we explored whether therapy with a CXCR4 antagonist-
armed oncolytic vaccinia virus activates endogenous
CD103+ dendritic cell responses associated with the induc-
tion of adaptive immunity against viral and tumor antigens.
The overall goal of this study was to determine whether
expansion of CD103+ dendritic cells by the virally delivered
CXCR4 antagonist augments overall survival and in situ
boosting with a tumor antigen peptide-based vaccine. We
found that locoregional delivery of the CXCR4-A-armed vi-
rus reduced the tumor load and the immunosuppressive
network in the tumor microenvironment, leading to inﬁltra-
tion of CD103+ dendritic cells that were capable of phago-
cytic clearance of cellular material from virally infected
cancer cells. Further expansion of tumor-resident CD103+
DCs by injecting the FMS-related tyrosine kinase 3 ligand,
the formative cytokine for CD103+ DCs, provided a platform
for a booster immunization with the Wilms tumor antigen 1
peptide-based vaccine delivered intraperitoneally with poly-
riboinosinic:polyribocytidylic acid as an adjuvant. The vac-
cine-induced antitumor responses inhibited tumor growth
and increased overall survival, indicating that expansion of
intratumoral CD103+ dendritic cells by CXCR4-A-armed on-
covirotherapy treatment can potentiate in situ cancer vaccine
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To be effective, cancer vaccine strategies need to promote the
release of tumor antigens in the context of immunogenic tumor
cell death (ICD), limit multiple levels of immunosuppression in
the tumor microenvironment (TME), and increase intratumoral
dendritic cell (DC) populations capable of stimulating cytotoxic
T cells and driving immune responses against cancer.1,2 Alongside
traditional ICD inducers like selected chemotherapies and
radiation (reviewed in Galluzzi et al.3), oncolytic viruses (OVs)Molecular Ther
This is an open access article under thave emerged as new members of this class of agents.4 Oncolytic
virotherapy has been recognized as a form of immunotherapy,
with a herpes simplex virus expressing granulocyte-macrophage
colony-stimulating factor (GM-CSF) recently approved by the
Food and Drug Administration5 and other vectors, including
vaccinia virus, undergoing extensive evaluation in multiple pre-
clinical and clinical trials.6–11 Although OVs have shown
limited clinical efﬁcacy as a monotherapy, emerging data suggest
that combination with conventional ICD-inducing chemothera-
peutic agents,8 checkpoint inhibitors to combat PD-1/PDL-1-
mediated immune suppression,12–14 and adjuvanted vaccines15
holds considerable promise. We have recently demonstrated that
the innate resistance properties of highly metastatic ovarian tu-
mors, together with the tumor immunosuppressive network, could
be overcome by the oncolytic vaccinia virus (OVV)-delivered
CXCR4 antagonist (CXCR4-A), which was particularly effective
in combination with doxorubicin-mediated killing.8 Because the
CXCL12/CXCR4 axis plays multiple pleiotropic roles in the
progression of ovarian cancer, including stimulation of vascular
endothelial growth factor (VEGF)-mediated angiogenesis,16 intra-
tumoral recruitment of endothelial progenitor cells,17 as well as
accumulation of CD11b+Gr1+ myeloid-derived suppressor cells
(MDSCs)18 and T regulatory cells (Tregs),19 modulation of this
axis affects innate and adaptive immune mechanisms of tumor
destruction by increasing T lymphocyte inﬁltration as well as
recently reported responses to checkpoint blockers.20 Therefore,
modulation of the CXCL12/CXCR4 axis in ovarian cancer could
affect multiple aspects of tumor pathogenesis, including immune
dysregulation.apy: Oncolytics Vol. 14 September 2019 ª 2019 The Author(s). 233
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Molecular Therapy: OncolyticsSeveral CXCR4 antagonists have demonstrated antitumor efﬁcacy
in preclinical models and have been evaluated in early clinical tri-
als.21–24 However, given the abundant expression of CXCR4 by
many cell types, including those of the CNS and gastrointestinal
and immune systems,25 the side effects of these antagonists need
to be taken into consideration. Furthermore, the effect of soluble
CXCR4 antagonists on the mobilization of CXCR4-expressing
bone marrow (BM)-derived stem and progenitor cells represents
an additional concern, particularly when combined with chemo-
therapeutic agents, because of the potential for adverse effects on
hematopoiesis.26,27 The potential effect of delivering a CXCR4-A
“payload” by OVV may also depend on the route of administration
of the armed virus, affecting both intratumoral viral titers and
accumulation of CXCR4-A at the tumor site or in systemic tissues.
This may affect the recruitment of immune cells, including the
CD103+ DCs or classical type 1 DCs (cDC1s), which excel in prim-
ing and cross-presentation of tumor antigens to CD8+ T cells, and
CD11b+ DCs or cDC2s, which are more potent at driving CD4+
helper T cell responses.28 Accumulating evidence suggests that tu-
mor lesions enriched in type I interferon (IFN)-induced genes are
also rich in T cells and that type I IFN production by the CD103+
DC lineage controls spontaneous T cell priming to tumor anti-
gens.29 On the other hand, defective recruitment and activation
of CD103+ DCs leads to reduced cross-priming of CD8+ T cells
and poorly inﬁltrated or “cold” tumors.30,31 Thus, increased
myeloid cell commitment to the CD103+ DC lineage and activa-
tion of intratumoral CD103+ DCs could substantially enhance
the effector phase of antitumor T cell responses.
Understanding the mechanisms that regulate the abundance of tu-
mor-inﬁltrating lymphocytes (TILs) in the TME could unveil new
therapeutic mechanisms. Because intratumoral DCs are necessary
for enhanced T cell tumor responses,2,32 we investigated the effect
of the armed oncolytic virotherapy (OVV-CXCR4-A) used alone or
in combination with the growth factor FMS-related tyrosine kinase
3 ligand (FLT3L; referred to hereafter as FL) on mobilization of inﬁl-
tration of CD103+ and CD11b+ DCs to the tumor site and induction
of T cell tumor responses. Using an intraperitoneal ovarian tumor
model (ID8-T) enriched for CD44+CD117+ cells with a cancer stem
cell-like phenotype,6 we showed that intraperitoneal delivery of the
CXCR4-A-armed vaccinia was more efﬁcacious in inhibiting tumor
growth compared with treatment with the soluble CXCR4-A
(sCXCR4-A) counterpart or a systemic injection of the armed virus
because of higher accumulation of the antagonist in tumors rather
than in systemic tissues. The armed virotherapy treatment increased
intratumoral accumulation of CD103+ DCs, and their subsequent
expansion by injection of the FL cytokine enhanced inﬁltration of an-
tigen-experienced CD8+ TILs and provided a platform for a booster
immunization with the WT1 peptide-based vaccine delivered with
polyriboinosinic:polyribocytidylic acid (poly(I:C)) as an adjuvant.
Our studies revealed that expansion of intratumoral CD103+ DCs
following CXCR4 antagonist-armed oncovirotherapy treatment rep-
resents a viable approach for in situ therapeutic vaccination to effec-
tively bolster antitumor immune responses.234 Molecular Therapy: Oncolytics Vol. 14 September 2019RESULTS
Inhibition of ID8-TOvarian TumorGrowth after Intraperitoneal or
Systemic Injection of CXCR4-A Delivered as a Soluble
Antagonist or by Oncolytic Virotherapy
We ﬁrst assessed the effect of intravenous (i.v.) or intraperitoneal
(i.p.) delivery of soluble and virally delivered CXCR4-A, expressed
in-frame with the murine Fc fragment of immunoglobulin G2a
(IgG2a; OVV-CXCR4-A), in C57BL/6 mice challenged i.p. with a
highly metastatic syngeneic ovarian cancer cell line (ID8-T). The
treatment was initiated 10 days after tumor challenge and consisted
of a single injection (108 plaque-forming units (PFUs)/mouse) of
OVV-CXCR4-A or control EGFP-expressing virus (OVV). To deter-
mine the contribution of the antagonist alone to controlling tumor
growth, additional tumor-bearing mice were treated for 7 days with
sCXCR4-A (10 mg/injection) delivered i.v. or i.p. or were injected
with RPMI-1640medium (control mice). Inhibition of tumor growth,
quantiﬁed by bioluminescence imaging, revealed rapid tumor
progression in untreated control mice (Figures S1A and S1B), with
animals reaching a humane endpoint within 4 weeks of challenge
(Figures 1A and 1B). Systemic delivery of OVV-CXCR4-A reduced
tumor growth and extended survival compared with untreated
controls (p < 0.001) or animals treated with the unarmed virus
(p = 0.002; Figure S1A). On the other hand, systemic injection of
sCXCR4-A demonstrated only modest effects in controlling tumor
spread and extended survival by 1 week compared with control tu-
mor-bearing mice. The antitumor effects of the virus or soluble antag-
onist were more pronounced after i.p. treatment (Figure S1B). I.p.
delivered OVV-CXCR4-A controlled tumor growth for 4–5 weeks,
and then the tumor progressed, extending survival by over 14 days
compared with mice treated with sCXCR4-A (p < 0.001; Figure 1B)
or by 10 days compared with the OVV-treated counterparts. A
combination of the control virus and sCXCR4-A delivered either
i.v. or i.p. was more efﬁcacious in reducing tumor growth (Figures
S1A and S1B) and increased survival compared with each treatment
alone (p < 0.05; Figures 1A and 1B). The combination, however, did
not achieve higher efﬁcacy compared with a single treatment with
OVV-CXCR4 (Figures 1A and 1B). This could be due to variations
in the distribution of sCXCR4-A in the TME after injection compared
with close contact of the antagonist with tumor stromata and cancer
cells after being released from OVV-CXCR4-A-infected cancer cells.
Differences in the level and physical contact of sCXCR4-A with can-
cer cells could directly affect tumor growth through induction of
apoptosis after binding to CXCR4-expressing ID8-T cells, followed
by phagocytosis of tumor cell debris by DCs (Figures S2A and
S2B), a process required for induction of antitumor immune
responses.8 Thus, the more efﬁcacious inhibition of ID-8-T tumor
growth by i.p. delivery of the antagonist, either by the virus or in a sol-
uble form, could be associated with higher concentrations of
sCXCR4-A in the tumor compared with systemic delivery, as
measured on day 8 after treatment (p < 0.01; Figures 1C and 1D).
The i.p. treatment also resulted in background levels of the antagonist
in sera or other organs, which was in contrast to2-fold higher levels
of sCXCR4-A detected in sera and lymphoid organs of mice after sys-
temic delivery. The higher concentrations of sCXCR4-A in the blood
Figure 1. Inhibition of ID8-T Tumor Growth and
Accumulation of sCXCR4-A in Peritoneal Washes of
Tumor-Bearing Mice, Sera, and Lymphoid Organs
after i.v. or i.p. Delivery of OVV-CXCR4-A and
sCXCR4-A
(A and B) C57BL/6 female mice (n = 5–10 mice/group)
were challenged i.p. with 3  105 ID8-T tumor cells and
treated with sCXCR4-A (10 mg/injection for 7 days), OVV
or OVV-CXCR4-A (108 PFU), or OVV and sCXCR4 com-
binations injected i.v. (A) or i.p. (B) 10 days after tumor
challenge. Control mice were treated with RPMI-1640
medium. Tumor progression was monitored by biolumi-
nescence. Kaplan-Meier survival plots were prepared,
and significance was determined using the log rank
method. *p < 0.05, **p < 0.01, ***p < 0.001. (C and D)
Accumulation of sCXCR4-A in peritoneal washes, sera,
and lymphoid organs of tumor-bearing mice after i.v. or
i.p. delivery of OVV-CXCR4-A (C) or sCXCR4-A (D) to
ID8-T tumor-bearing mice. Concentrations of sCXCR4-A
in sera, peritoneal washes (denoted as tumors), livers,
BM, lymph nodes, and spleens were determined on day 8
after treatment by ELISA after normalization to total pro-
tein content. Data are presented as the mean ± SD of five
mice per group. **p < 0.01, ***p < 0.001.
www.moleculartherapy.organd systemic tissues after i.v. injection compared with i.p. delivery
were associated with 10% increased numbers of leukocytes in the
peripheral blood on days 8 and 15 before returning to baseline on
day 30, although the treatment had no effect on red blood cell and
platelet counts (Figures S3A–S3C).
Reduction of Intratumoral Immune Suppression and Enhanced
Infiltration of CD103+ DCs after OVV-CXCR4-A Treatment
Previous studies have shown that virally delivered CXCR4 antagonist
blocks the CXCL12/CXCR4 axis involved in tumor progression by
inhibiting local immunosuppression.6–8,20 Therefore, we next investi-
gated the effects of sCXCR4-A and OVV-CXCR4-A treatments on in-
tratumoral accumulation of granulocyte-like myeloid-derived sup-
pressor cells (G-MDSCs) and Tregs within the TME by ﬂow
cytometry analyses performed 8 days later, which roughly corre-
sponded to the termination of viral replication in vivo.6 As shown
in Figure 2A, the frequencies of tumor-inﬁltrating CD45+ leukocytes
in tumor-bearing mice after virotherapy treatments were 4-fold
higher compared with those in the untreated or sCXCR4-A-
treated counterparts. The antagonist, delivered i.p. as a soluble pro-
tein or secreted from virally infected tumor cells, reduced the accu-
mulation of immunosuppressive CD11b+Ly6ClowLy6Ghigh G-MDSCs
compared with the untreated and OVV-treated counterparts (Fig-
ure 2B; p = 0.03 and p = 0.006, respectively), and also inhibited
accumulation of CD4+CD25+Foxp3+ Tregs (Figure 2C; p < 0.05). In-
hibition of the immunosuppressive network within the TME contrib-
uted to increased accumulation of CD8+ TILs, which were detected
after sCXCR4-A delivery (p = 0.02) and increased by over 3-fold afterOVV or OVV-CXCR4-A treatment (Figure 2D; p < 0.01). The viro-
therapy-expanded CD8+ TILs consisted mostly of antigen-experi-
enced (CD44hiCD62L+ and CD44hiCD62L) cells with less than 5%
naive (CD44loCD62L+) and double-negative cells (Figure 2E), which
was in contrast to the predominantly naive phenotype of CD8+ TILs
in untreated mice. Treatment with sCXCR4-A increased the fre-
quencies of CD44hiCD62L+ and CD44hiCD62L CD8+ cells
compared with control mice, but the changes were not signiﬁcant.
The increased percentages of CD8+ TILs after oncovirotherapy treat-
ment were associated with higher inﬁltration of tumor-associated
macrophages (TAMs) and DCs, proﬁled within the CD45+ compart-
ment using multi-color ﬂow cytometry and a progressive gating
strategy.33 As shown in Figures 3A–3D, subgating all CD45+ hemato-
poietic cells by the myeloid-speciﬁc marker CD11b that were Ly6C-
negative allowed removal of neutrophils (CD11b+Ly6Clo) and
monocytes (CD11b+Ly6Chi). Within the CD11b+MHCII+ subset,
macrophages were distinguished from DCs based on CD24lo and
F4/80hi expression, and because neither marking alone is sufﬁcient
to make this distinction,33 these two populations were analyzed sepa-
rately. Staining of the F4/80hiCD24lo cells with CD11b and CD11c
showed that the majority of macrophages exhibited the
CD11bhiCD11clo phenotype, captured by the TAM1 subset of
macrophages,33 with only small proportions being double-positive
for both antigens and CD11chiCD11bhi in all treatment groups. The
results, presented as the percentages of TAMs within CD45+ cells, re-
vealed that the relative proportions of F4/80+CD11bhiCD11clo cells
were higher in treatment groups compared with control miceMolecular Therapy: Oncolytics Vol. 14 September 2019 235
Figure 2. Increased Inflammation and Inhibition of
the Immunosuppressive Network in the TME by
Virally Delivered CXCR4-A
(A–D) Accumulation of leukocytes (CD45+) (A), G-MDSCs
(CD11b+Ly6GhiLy6Clo) (B), Tregs (CD4+CD25+Foxp3+)
(C), and CD8+ T cells (D) in peritoneal washes of ID8-T
ovarian tumor-bearing mice was analyzed by flow cy-
tometry 8 days after treatment. (E) Memory subsets of
CD8+ T cells were analyzed with mAbs specific for CD44
and CD62L antigens. Background staining was assessed
using isotype control antibodies. Data are mean ± SD of
three or four independent experiments. *p < 0.05,
**p < 0.01, ***p < 0.001.
Molecular Therapy: Oncolytics(Figure 3E; p < 0.05), whereas no signiﬁcant differences were observed
in the proportions of F4/80+CD11chiCD11bhi cells (Figure 3F). This
was in contrast to increased percentages of CD11b+ and CD103+
DCs within the F4/80loCD24hi population after virotherapy treat-
ments (Figures 3G and 3H; p < 0.05) with signiﬁcantly higher
numbers of CD103+ DCs in OVV-CXCR4-A-treated tumors
compared with OVV-treated counterparts (p = 0.04).
FL-Mediated Expansion of Intratumoral CD103+ DCs Inhibited
Tumor Growth and Augmented Infiltration of CD8+Ly6C+ TILs
Given the profound association of intratumoral stimulatory DCs with
patient outcome,34 we sought to determine whether expansion of
CD103+ DCs in the TME would enhance the therapeutic efﬁcacy of
the combined treatment by promoting tumor antigen presentation
and priming of T cells following virotherapy-mediated ICD.35 The
formative cytokine for cDC1s, which include tumoral CD103+ DCs,
is FL, which is predominantly produced by lymphocytes, notably nat-
ural killer cells in mouse and human tumors.2 Because the antitumor
effect of oncolytic virotherapy is short-lasting because the virus is
eliminated by the innate and adaptive immune responses, we hypoth-
esized that the paucity of CD103+ DCs at the tumor site restricted the
expansion of tumor-speciﬁc CD8+ T cells and, therefore, limited the
efﬁcacy of the viroimmunotherapy treatment. We therefore sought to
determine whether expansion of intratumoral CD103+ DCs by local
delivery of the FL growth factor36 would enhance the therapeutic ef-
ﬁcacy of the combined treatment by promoting tumor antigen pre-
sentation and priming T cells following virotherapy-mediated
ICD.35 As depicted in Figure 4A, 8 days after virotherapy treatment,
tumor-bearing mice were injected i.p. with FL (5 mg/injection) for
4 days, and changes in tumor-inﬁltrating DCs were analyzed 2 days236 Molecular Therapy: Oncolytics Vol. 14 September 2019later by ﬂow cytometry. As shown in Figures
4B and 4C, injection of the FL cytokine
expanded over 2-fold (p < 0.05) the frequency
of CD103+ DCs among the MHCII+F4/
80loCD24hi cell population in both OVV and
OVV-CXCR4-A-treated tumor-bearing mice
(Figures 4B–4E). The combination treatment-
expanded CD103+ DCs were able to engulf
cellular debris from OVV-exposed ID8-T cells
at higher levels compared with their virother-apy-expanded counterparts (Figure 4D; p % 0.04), which is strin-
gently required for mounting an immune response against dying
tumor cells.8 The FL-mediated increases in CD103+ DCs in tumor-
bearing mice were associated with decreased tumor growth (Fig-
ure 4E) compared with animals receiving monotherapy with OVV
(p = 0.04) or OVV-CXCR4-A (p = 0.03).
Because intratumoral inﬁltration of CD103+ DCs is one of the major
requirements for establishing a T cell-inﬂamed tumor phenotype
because of production of CXCL9 and CXCL10 chemokines, which
promote recruitment of effector CXCR3+ CD8+ T cells,37 we next
examined whether this mechanism could also be used to increase
survival and bolster tumor-speciﬁc T cell responses following viro-
therapy. For the analysis, CD8+ T cells in the peritoneal cavities of
control and virotherapy-treated mice were stained with antibodies
speciﬁc to Ly6C antigen expressed on antigen-experienced T cells38
as well as tetramers speciﬁc for the vaccinia virus B8R protein
(B8R-Kb/TSYKFESV) and WT1 tumor antigen (WT1-2Db/
RMFPNAPYL). Figures 5A and 5B show a more than 3-fold expan-
sion of intratumoral CD8+Ly6C+ cells after OVV treatment
compared with control mice (p < 0.001), and the numbers increased
by 30% after FL delivery (p < 0.05). The increased percentages of
antigen-experienced CD8+Ly6C+ TILs after OVV and FL combina-
tion treatment extended themedian survival rate (45 days; Figure 5C)
compared with OVV-treated and control groups of mice (33 and
27 days, respectively). Because injection of the FL cytokine into un-
treated mice did not affect the survival rate, it appears that virother-
apy-mediated accumulation of intratumoral DCs and changes in the
TME are required for the FL-mediated antitumor effect. Over 10% of
CD8+ TILs in mice that received oncolytic virotherapy treatments
Figure 3. Intratumoral Infiltration of CD103+ DCs after i.p. Treatment with Soluble or Virally Delivered CXCR4-A
(A–D) Representative flow cytometry staining and gating of myeloid cell populations infiltrating the peritoneal cavities of ID8-T-challenged mice treated with medium (A),
sCXCR4-A protein (B), OVV (C), and OVV-CXCR4-A (D). (E–H) Relative proportions of tumor-infiltrating F4/80+CD11bhiCD11clo (E), F4/80+CD11bhiCD11chi (F), CD11b+
DCs (G), and CD103+ DCs (H) are depicted as percentages of total CD45+ cells. Results are presented as mean ± SD from three or four independent experiments. *p < 0.05,
**p < 0.01, ***p < 0.001.
www.moleculartherapy.orgwere positive for the B8R-Kb/TSYKFESV vaccinia-speciﬁc tetramer,
with additional increases in the percentages of tetramer-positive cells
measured after FL delivery (Figures 5D and 5E). However, despitesigniﬁcant increases in the frequencies of CD8+Ly6C+ TILs,
including those that were directed against the viral antigen, percent-
ages of WT1 tetramer+CD8+ T cells were at background levels afterMolecular Therapy: Oncolytics Vol. 14 September 2019 237
Figure 4. Expansion of Intratumoral CD103+ DCs by
Local Delivery of the FL Cytokine Enhances the
Efficacy of Oncolytic Virotherapy Treatment
(A) Graphical timeline of the treatment scheme in ID8-T
tumor-bearing mice. C57BL/6 mice were injected i.p. with
3  105 ID8-T cells. Treatment with OVV or OVV-
CXCR4-A (108 PFU delivered i.p.) was initiated 10 days
later. To expand CD103+ DCs, FL was injected i.p. at
5 mg/injection for 4 consecutive days, beginning on day 8
after virotherapy treatment. Percentages of CD11b+ and
CD103+ DCs in peritoneal washes of OVV- or OVV-
CXCR4-A-treated, ID8-T-bearing mice (n = 3–5 mice/
group) after i.p. delivered FL were analyzed 2 days later,
whereas percentages of CD8+ TILs were assessed on day
32 by flow cytometry. (B and C) Relative proportions (left
panel) and representative flow cytometry plots (right panel)
of intratumoral CD11b+ and CD103+ DCs within MHCII+
F4/80loCD24hi populations of myeloid cells infiltrating the
peritoneal cavities of ID8-T tumor-bearing mice after OVV
and FL treatment (B) as well as OVV-CXCR4-A and FL
treatment (C). Results are presented as mean ± SD of four
experiments. *p < 0.05, **p < 0.01. (D) FL-mobilized
CD103+ DCs exhibited increased phagocytosis of tumor
cell debris. CD45+ leukocytes isolated from peritoneal
cavities of ID8-T tumor-bearing mice 2 days after treat-
ment with OVV or OVV-CXCR4-A alone or in combination
with FL were cultured with OVV-treated and CellTracker-
labeled ID8-T cancer cells. After overnight incubation, the
capture of tumor-associated fluorescent debris by
CD103+ DCs was analyzed by flow cytometry. Percent-
ages of phagocytosis of virally treated tumor cell debris by
CD103+ DCs are presented as mean ± SD of 3 experi-
ments. *p < 0.05. (E) Progression of ID8-T tumor growth in
mice (n = 5 mice/group) treated with OVV or OVV-
CXCR4-A delivered alone or in combination with the FL
cytokine was monitored by bioluminescence. Data points
represent mean ± SD. *p < 0.05.
Molecular Therapy: Oncolyticsoncolytic virotherapy and FL combination treatment (Figures 5F and
5G). CD8+Ly6C+ T cell responses were increased after the OVV-
CXCR4-A and FL treatment combination compared with tumor-
bearing mice treated with the control virus and FL (p = 0.016; Figures
5H and 5I) and were associated with an increased survival rate (Fig-
ure 5J). The higher percentages of B8R tetramer+CD8+ TILs in OVV-
CXCR4-A-treated mice compared with those receiving the control
virus with or without FL treatment (p < 00.4; Figure 5K) also indi-
cated that the release of CXCR4-A from virally infected tumor cells
did not interfere with migration of antigen-speciﬁc T cells to the
TME, consistent with minimal expression of CXCR4-A on differen-
tiated effector and effector memory T cells.39 It is also notable that238 Molecular Therapy: Oncolytics Vol. 14 September 2019the percentages of B8R tetramer+CD8+ T cells
in spleens and tumors, measured after single
or multiple (3 times) deliveries of the oncolytic
viruses, were similar (Figures S4A–S4C),
possibly because of acquired resistance of resid-
ual tumors to repeated viral infections. How-
ever, despite the higher frequencies ofB8R-Kb/TSYKFESV tetramer+CD8+ TILs after OVV-CXCR4-A
and FL treatment compared with those generated using the control
virus combination (p < 0.05), the percentages of WT1 tetramer+
CD8+ T cells still remained at background levels (Figure 5L). There-
fore, we hypothesized that a weak expression level of the WT1
protein in ID8-T cancer cells, together with an excess of highly
phagocytic macrophages in the TME, which compete for antigen
availability at the tumor site, could limit the ability of CD103+ DCs
to prime and activate sufﬁcient numbers of WT1 tetramer+CD8+
T cells. We next investigated whether boosting the load of WT1 an-
tigen at the tumor site with an adjuvanted WT1 peptide-based vac-
cine would enhance the frequencies of WT1 tetramer+CD8+ TILs.
Figure 5. FL-Mediated Expansion of Intratumoral CD103+ DCs Inhibits Tumor Growth and Augments Infiltration of CD8+ TILs to Peritoneal Cavities of ID8-T
Tumor-Bearing Mice
(A and B) Evaluation of tumor-infiltrating CD8+Ly6C+ T cells in peritoneal washes after OVV treatment alone or in combination with the FL cytokine (n = 5 mice/group).
Representative flow cytometry staining (A) and relative proportions of CD8+Ly6C+ TILs (B) are shown. (C) Survival of ID8-T tumor-bearing C57BL/6 mice (n = 5–10 mice/
group) after OVV and OVV plus FL treatment combinations. Survival was defined as the point where mice were killed because of extensive tumor burden. Kaplan-Meier
survival plots were prepared, and significance was determined using the log rank method. **p < 0.01, ***p < 0.001. (D and E) Representative flow cytometry staining (D) and
relative proportions of a tumor-infiltrating B8R vaccinia virus-specific tetramer+ subset of CD8+ TILs (E). (F and G) Representative flow cytometry staining (F) and relative
proportions of WT1 tetramer+CD8+ TILs (G). (H and I) Evaluation of tumor-infiltrating CD8+Ly6C+ T cells in peritoneal washes after OVV-CXCR4-A treatment alone or in
combination with the FL cytokine (n = 3–5 mice/group). Representative flow cytometry staining (H) and relative proportions of the CD8+Ly6C+ TILs (I) regimen are shown. (J)
(legend continued on next page)
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Molecular Therapy: OncolyticsGeneration of WT1-Specific CD8+ TILs by an Adjuvanted WT1-
Peptide Vaccine Delivered after Oncovirotherapy and FL
Treatment Required Batf3-Driven CD103+ DCs
The WT1-speciﬁc peptide containing H2-IAb-restricted
CRYGPFGPPPSQAS and H2-Db-restricted RMFPNAPYL epi-
topes6,8 was injected i.p. to ID8-T-bearing mice (50 mg/injection)
3 days after FL delivery (Figure 6A) in combination with poly(I:C)
(50 mg/injection), which binds to TLR3 expressed on CD103+
DCs40 and induces type I IFN production and DC maturation.41,42
Additional groups of tumor-bearing mice received only virotherapy
treatments before immunization to determine the importance of
FL-expanded CD103+ DCs in the induction of tumor-antigen-speciﬁc
T cells and inhibition of tumor growth. As shown in Figure 6B, vacci-
nation of mice after OVV and FL treatment combination exhibited
potent antitumor activities, extending survival by about 15 days
compared with mice treated with the virus (p < 0.001) and by
7–8 days compared with the virus and WT1 vaccine (p = 0.006).
This regimen also elicited measurable WT1-speciﬁc CD8+ T cell re-
sponses compared with those induced by vaccination without prior
FL treatment (p = 0.03; Figures 6C and 6D). CXCR4-A-armed viro-
therapy followed by FL-mediated expansion of CD103+ DCs prior
to vaccination was most effective in inhibiting tumor growth (median
survival of 69 days; Figure 6E) and inducingWT1-2Db/RMFPNAPYL
tetramer+CD8+ TILs (Figures 6F and 6G). Additional experiments
performed in Batf3/ knockout mice deﬁcient for both CD103+
and CD8a+ DCs29,43 revealed an absence of the WT1 vaccine-medi-
ated protective responses (Figure 6H), stressing the need for CD103+
DCs at the tumor site for induction of antitumor protective immune
responses.
DISCUSSION
As cancer therapies continue to evolve and incorporate immuno-
therapy as an integral aspect of treatment, developing approaches
that potentiate the induction of ICD and overcome non-T cell
inﬂamed tumors will be important to realizing increased treatment ef-
ﬁcacy. Here we showed that locoregional delivery of the CXCR4-A-
armed virus is more efﬁcacious in inhibiting orthotopic growth of
ovarian tumors than i.v. injection of the unarmed counterpart,
possibly because of a higher accumulation of the antagonist in the tu-
mor than in systemic tissues. It also appears that distribution of the
CXCR4 antagonist in the TME and its vicinity to both stromal and
cancer cells play an important role in blocking the CXCL12/CXCR4
signaling pathway. For example, physical contact of the antagonist
with the target can be more efﬁcacious when it is released from virally
infected cancer cells directly to the TME than delivered by injection
because the latter form of delivery may not facilitate effective penetra-
tion in the tumor tissue. This hypothesis is consistent with higher in-
hibition of tumor growth by i.p. delivery of OVV-CXCR4-A virus
than by injection of the soluble antagonist with a control virus bySurvival of ID8-T tumor-bearing C57BL/6 mice (n = 5–10 mice/group) after OVV-CXCR
were prepared, and significance was determined using the log rank method. **p < 0.
proportions of a tumor-infiltrating B8R vaccinia virus-specific tetramer+ subset (L) afte
cytometry staining (M) and relative proportions of WT1 tetramer+CD8+ TILs (N).
240 Molecular Therapy: Oncolytics Vol. 14 September 2019the same route. The results of our studies are in agreement with the
recent work by Chen et al.,20 demonstrating that high concentrations
of localized CXCR4-A in the TME decreases immunosuppression
associated with enhanced inﬁltration of CD8+ TILs and inhibition
of tumor growth. This, together with the ﬁndings that the TME
may regulate clonal expansion of cancer-speciﬁc T cells44 and that
CD8+ T cell proliferative responses are orchestrated by CD103+
Baft3-dependent DCs32 suggest dependence of T cell-mediated tumor
regression on the intratumoral presence of CD103+ DCs. Thus, ther-
apeutic interventions that enhance inﬁltration of intratumoral stimu-
latory DCs and their capacity for driving T cell proliferation may
contribute to tumor control. Among such strategies are interventions
that target intratumoral TAMs and MDSCs and lead to reduced tu-
mor burdens in preclinical models in both T cell-dependent and
T cell-independent ways. For instance, inhibiting chemokine receptor
type 2 (CCR2),45 colony-stimulating factor-1 receptor (CSF-1R),45,46
and GM-CSF47 in preclinical models of melanoma and pancreatic,
breast, and prostatic carcinoma increased intratumoral T cells and
controlled tumor growth, especially when combined with anti-
CTLA-4 or anti-PD-1/PD-L1. Although these studies did not deter-
mine whether the increases in T cells were a consequence of enhanced
viability or proliferation, they emphasize that elements of the TME
regulate the accumulation of effector T cells. In addition, the distribu-
tion of intratumoral CXCL12, which correlates inversely with that of
T cells, suggests that CXCL12 is involved in T cell exclusion based on
the antitumor outcome of inhibiting CXCR4. The results of our recent
studies further emphasize this assumption and demonstrate that
CXCR4-A-armed oncolytic virotherapy treatment was associated
with increases in intratumoral accumulation of CD103+ DCs and
that its efﬁcacy could be further boosted by FL-mediated expansion
of CD103+ DCs.
By inducing ICD and antigen release at the tumor site via viral oncol-
ysis with simultaneous reprogramming of the TME, the armed viro-
therapy is personalized and can be combined with tumor-speciﬁc
vaccines48,49 after increasing the intratumoral inﬁltration of
CD103+ DCs by injection of the FL cytokine. As demonstrated
here, intratumoral accumulation of CD103+ DC populations at the
tumor site served as a platform for the adjuvanted WT1-speciﬁc pep-
tide vaccine booster, leading to generation of WT1 tetramer+CD8+
TILs and increases in overall survival. This approach could be used
with a variety of tumor-associated antigens as an “off-the-shelf” prod-
uct for immunization or with personalized neoantigen-speciﬁc
epitopes, the presence of which has been shown to correlate with
expression of immune-related genes and efﬁcacy of checkpoint inhib-
itor therapy.50 Thus, the described “in situ vaccination” strategy is
feasible and effective in inducing and amplifying T cell responses to
tumor antigens. Because a high mutational burden has been associ-
ated with an increased neoantigen load and TILs, which improved4-A and OVV-CXCR4-A plus FL treatment combination. Kaplan-Meier survival plots
01, ***p < 0.001. (K and L) Representative flow cytometry staining (K) and relative
r combined treatment with OVV-CXCR4-A and FL. (M and N) Representative flow
Figure 6. An Adjuvanted WT1 Vaccine Delivered after Oncovirotherapy and FL Treatment Combination Generates WT1-Specific CD8+ TILs and Requires
Batf3-Driven CD103+ DCs
(A) Graphical timeline of the treatment scheme in ID8-T tumor-bearing mice. C57BL/6 mice were injected i.p. with 3 105 ID8-T cells. Treatment with OVV or OVV-CXCR4-A
(108 PFU delivered i.p.) was initiated 10 days later. To expand CD103+ DCs, FL was injected i.p. at 5 mg/injection for 4 consecutive days, beginning on day 8 after virotherapy
treatment. The WT1-specific peptide was delivered i.p. (50 mg/injection) with poly(I:C) (p(I:C); 50 mg/injection) on day 3 after the last FL delivery. (B) Survival of ID8-T tumor-
bearing mice (n = 5–10 mice/group) after WT1 immunization of OVV- and OVV plus FL-treated mice. Kaplan-Meier survival plots were prepared, and significance was
determined using the log rank method. **p < 0.01. (C and D) Representative flow cytometry staining (C) and relative proportions of WT1 tetramer+CD8+ TILs (D) after
combined treatment of OVV and WT1 vaccine as well as OVV and FL treatment followed by WT1 vaccination (n = 4–5 mice/group). (E) Survival of ID8-T tumor-bearing mice
(legend continued on next page)
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Molecular Therapy: Oncolyticsclinical outcomes and survival seen in patients with tumors, incorpo-
rating novel peptide sequences that result from protein-changing so-
matic mutation in cancer cells will be of utmost value.51 The ability of
intratumoral virotherapy to broaden the neoepitope spectrum when
delivered with systemic PD-1 checkpoint inhibition, resulting in
improved antitumor efﬁcacy,52 is consistent with the observation
that oncolytic viruses may not only be used as direct tumor therapy
but may also serve as a method to validate the responsiveness of
T cells to predicted neoepitopes.53
The CXCR4-A oncolytic virotherapy-generated immunogenic tumor
cell “cargo” for DC loading has the potential to be further enhanced
by combination with ICD-inducing chemotherapeutic agents, such as
doxorubicin, to promote improved antigen presentation to T cells54
because of a synergistic interaction between OVV and doxorubicin.8
This synergy could increase the amount of tumor antigens for cross-
priming and broaden the diversity of danger-associated molecular
patterns (DAMPs). We also found that CXCR4-A, by binding to its
cognate receptor on cancer cells and inducing apoptosis, was capable
of increasing phagocytosis of tumor cell debris by DCs and, therefore,
appears to indirectly improve the efﬁcacy of virotherapy. This effect
could be further augmented through an interaction with the Fcg re-
ceptors (FcgRs) on phagocytes because the antagonist, expressed as a
fusion protein with the Fc portion of IgG2a, has been shown to
eliminate tumor cells through the antibody-dependent cellular cyto-
toxicity (ADCC) mechanism,6,7 helping to achieve the desirable
induction of antitumor immunity. In such a context, high concentra-
tions of sCXCR4-A after locoregional delivery could be relevant in
immunotherapies of cancer cells with deregulated type I IFN
signaling pathways55 because FcgR-mediated antibody-dependent
cellular phagocytosis bypasses the need for canonical phagocytic de-
terminants. Such IgG-bound target cells can be efﬁciently processed,
and the resulting tumor antigens can be used for cross-presentation
by antigen-presenting cells (APCs), enhancing the repertoire of can-
cer antigen-directed T cell responses.56
Because the absence of CD103+ DCs in the TME may be a critical
rate-limiting step for initiating endogenous CD8+ T cell responses
against cancer,31 our results argue that CXCR4-A-armed virotherapy
followed by FL treatment is effective in the expansion of intratumoral
CD103+ DCs. The observed lack of interference of the CXCR4-A with
DC inﬁltration is in agreement with previous studies, which showed
that trafﬁcking of DCs occurs in a coordinated, stepwise fashion, with
CXCR4 and CXCL12 promoting the retention of pre-DCs in the BM
but not migration to peripheral tissues and regional lymph nodes,
which are directed by CCR2/CX3CR1 and CCR7, respectively.57
Similarly, the lack or minimal expression of CXCR4 on differentiated
effector T cells58 explains the relatively high numbers of CD8+ TILs
expressing the Ly6C antigen, known to be associated with the effector(n = 5–10 mice/group) after WT1 immunization of OVV-CXCR4-A and OVV-CXCR4-A pl
staining (F) and relative proportions of WT1 tetramer+CD8+ TILs (G) after combined tre
followed by WT1 vaccination (n = 4–5 mice/group). (H) Survival of ID8-T tumor-bearing
bination with FL and the WT1 adjuvanted vaccine. Kaplan-Meier survival plots were pr
242 Molecular Therapy: Oncolytics Vol. 14 September 2019and effector memory phenotypes.38 Furthermore, the background
levels of the CXCR4 antagonist in the blood and systemic tissues after
i.p. treatment with OVV-CXCR4-A precluded any meaningful
interference with the CXCR4-CCR5 interaction at the immunological
synapse during T cell activation by APCs,59 despite high CXCR4
expression on naive and central memory T cells (TCM).
58 It should
also be realized that CXCR4-A-armed virotherapy treatment may
have a profound effect on the induction of immune cells exhaustion,
in view of recent studies showing that CXCR4 inhibition improves re-
sponses to immune checkpoint blockers in mice bearing metastatic
breast cancers20 as well as decreases CD4+ T cell exhaustion and im-
proves survival in a murine model of polymicrobial sepsis.39 Alto-
gether, our study identiﬁes combination therapies to potentiate ICD
as well as the recruitment of CD103+ DCs to tumor sites for an effec-
tive in situ vaccination, which holds promise for the development of
more efﬁcacious treatments for cancer patients.
MATERIALS AND METHODS
Animals and Cell Lines
Female C57BL/6 mice were obtained from Charles River Laboratories
(Wilmington, MA, USA). B6.129S(C)-Batf3tm1Kmm/J mice were pur-
chased from The Jackson Laboratory (Sacramento, CA, USA). Exper-
imental procedures were performed in compliance with protocols
approved by the Institutional Animal Care and Use Committee of
the Roswell Park Comprehensive Cancer Center (RPCCC, Buffalo,
NY, USA). The parental ID8 mouse ovarian epithelial cell line,
derived from spontaneous malignant transformation of C57BL/6
MOSE cells,60 and its metastatic variant ID8-T were established in
our laboratory at the RPCCC.6 Human HuTK 143 ﬁbroblasts, hu-
man cervical carcinoma HeLa cells, and the African green monkey
cell line CV-1 were obtained from the American Type Culture Collec-
tion (Manassas, VA, USA).
Viruses
All vaccinia viruses used in this study were of the Western Reserve
strain, with disrupted thymidine kinase and vaccinia growth factor
genes for enhanced cancer cell speciﬁcity. The generation and charac-
terization of OVVs expressing EGFP, the Fc portion of murine IgG2a,
and CXCR4-A in the context of the Fc portion of murine IgG2a have
been described.7 The CXCR4-A fusion protein was collected in super-
natants of infected HuTK 143 cells and puriﬁed on a protein G
column (GE Healthcare Life Sciences, Pittsburgh, PA, USA) as
described.7
ELISA
Concentrations of the soluble CXCR4-A protein in sera, cell lysates
from systemic tissues, and peritoneal washes of tumor-bearing mice
were measured by ELISA on day 8 after treatment using plates coated
with a recombinant human CXCR4 protein, MEGISIYTSDNYus FL-treated mice. *p < 0.05, ***p < 0.001. (F and G) Representative flow cytometry
atment of OVV-CXCR4-A and WT1 vaccine and OVV-CXCR4-A plus FL treatment
Batf3/ female mice (n = 5) after treatment with OVV-CXCR4-A alone or in com-
epared, and significance was determined using the log rank method. ***p < 0.001.
www.moleculartherapy.orgTEEMGSGDYDSMKEPCFREENANFNKIFLPTIYS (Abcam, Cam-
bridge, MA, USA), followed by incubation with goat anti-mouse Fc
portion-speciﬁc horseradish peroxidase (HRP)-conjugated antibody
(Sigma-Aldrich, St. Louis, MO, USA), and the reaction was developed
with 1-Step Ultra TMB-ELISA reagent (Thermo Fisher Scientiﬁc,
Grand Island, NY, USA). In parallel, protein levels in each sample
were determined by the Bradford method with protein assay dye re-
agent (Bio-Rad, Hercules, CA, USA).
In Vitro Phagocytosis Assays
CD45+ leukocytes isolated from peritoneal cavities of ID8-T-bearing
mice 2 days after virotherapy treatment alone or in combination with
FL were analyzed for their ability to engulf tumor cell debris from vir-
ally treated cultures. ID8-T cells were labeled with CellTracker Blue
CMF2HC and treated with OVV at an MOI of 1 for 24 h before incu-
bation with DCs (1:1 ratio) for 12 h. Tumor cells were treated with
UV light (365 nm for 3 min) in the presence of 10 mg/mL psoralen
to inactivate the virus. After overnight incubation, the capture of tu-
mor-associated ﬂuorescent debris by CD103+ DCs was analyzed by
ﬂow cytometry. For some experiments, BM cells were ﬂushed from
the tibiae and femora of C57BL/6 mice and cultured in medium sup-
plemented with 10 ng/mL of GM-CSF for 6 days as described.61 After
7 days, non-adherent and loosely adherent cells were harvested,
washed, and co-cultured with tumor cells labeled with CellTracker
Blue CMF2HC (Thermo Fisher Scientiﬁc, 1:1 ratio) for 12 h.
Treatments of Established Tumors
C57BL/6 mice (n = 5–10) were injected i.p. with 3  105 ID8-T cells.
Treatments with sCXCR4-A (10 mg/injection for 7 days), OVV, and
OVV-CXCR4-A (108 PFU), delivered i.v. or i.p., were initiated
10 days later. Tumor progression was monitored by bioluminescence
imaging using the Xenogen IVIS Imaging System (PerkinElmer, Wal-
tham, MA, USA) as described.8 Control mice received RPMI-1640
medium or UV-inactivated virus. At the end of the experimental
period, corresponding to the development of bloody ascites in control
mice, tumor-bearing mice were sacriﬁced, and organs were examined
for tumor development and metastatic spread. For in situ immuniza-
tion of ID8-T tumor-bearing mice, the FL cytokine (BioLegend, San
Diego, CA, USA) was delivered i.p. (5 mg/injection) for 4 consecutive
days, beginning on day 8 after virotherapy treatment, followed by
the WT1-speciﬁc peptide vaccine (amino acids [aa] 175–202;
CRYGPFGPPSQASSGOARMFPNAPYL; 50 mg/injection; GenScript,
Piscataway, NJ, USA) and 50 mg/mouse of poly(I:C) (Sigma-Aldrich),
delivered i.p. on day 3 after the last FL injection. Progression of tumor
growth was analyzed by bioluminescence.
Flow Cytometry
The induction of apoptosis or necrosis in ID8-T cells treated with
sCXCR4-A (10 mg/mL), OVV, or OVV-CXCR4-A (MOI = 1) was
determined by staining with Annexin V- ﬂuorescein isothiocyanate
(FITC) and LIVE/DEAD ﬁxable violet (Thermo Fisher Scientiﬁc) ac-
cording to the manufacturer’s instructions. Phenotypic analysis of tu-
mor-inﬁltratingmyeloid cells and T cells was performed on single-cell
suspensions prepared from peritoneal ﬂuid collected 8 days aftercompletion of the treatments. All antibodies were purchased from
BD Pharmingen (San Jose, CA, USA), BD Biosciences (San Jose,
CA, USA), and BioLegend, as detailed in Table S1. The phycoerythrin
(PE)-labeled H-2Db/RMFPNAPYL tetramer WT1 and PE-labeled
H2-Kb/TSYKFESV vaccinia virus-speciﬁc tetramer B8R were ob-
tained from the MHC Tetramer Production Facility (Baylor College
ofMedicine, Houston, TX,USA). Percentages of CD4+T cells express-
ing Foxp3 were determined by intracellular staining using the BD
Pharmingen Transcription Factor Buffer Set (BDBiosciences) accord-
ing to themanufacturer’s protocol. For tetramer analysis, lymphocytes
were also gated on cells that were negative for CD11b expression.
Background staining was assessed using isotype control antibodies.
Before speciﬁc antibody staining, cells were incubated with Fc blocker
(anti-CD16/CD32 mAb) for 10 min and analyzed on the LRS II ﬂow
cytometer (BD Biosciences). Data analysis was performed using
WinList 3D 7.1 (Verity Software House, Topsham, ME, USA).
Statistical Analysis
All statistical analyses were performed using GraphPad Prism 6
(GraphPad, La Jolla, CA, USA). Unless otherwise noted, data are pre-
sented as mean ± S.D. combined with unpaired, two-tailed Student’s
t test. Kaplan-Meier survival plots were prepared, and median sur-
vival times were determined for tumor-challenged groups of mice.
Statistical differences in survival across groups were assessed using
the log rank Mantel-Cox method. The threshold for statistical signif-
icance was set to p < 0.05.
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